Kavanaugh Arthur, Coates Laura C, van der Windt Danielle A, Corp Nadia, Soriano Enrique R
From the Division of Rheumatology Allergy and Immunology, University of California, San Diego, La Jolla, California, USA; Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford; Primary Care Centre Versus Arthritis, School of Primary, Community and Social Care, Keele University, Staffordshire, UK; Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego; L.C. Coates, MB ChB, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford; D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Primary, Community and Social Care, Keele University; N. Corp, PhD, Primary Care Centre Versus Arthritis, School of Primary, Community and Social Care, Keele University; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires.
J Rheumatol Suppl. 2020 Jun;96:41-45. doi: 10.3899/jrheum.200126.
The development and updating of treatment recommendations for optimal treatment approaches for patients with psoriatic arthritis (PsA) has been an important mission of the Group for Research and Assessment of Psoriasis and PsA (GRAPPA) since its inception. Even though the most recent iteration of the GRAPPA PsA recommendations was completed only a few years ago, there have been many significant advances related to therapies and treatment approaches for PsA since their publication. Because of these advances, the process to update the recommendations again has begun. The standard approaches to guideline (or treatment recommendation) development have also evolved in recent years. Herein, the basis for the approach that will be taken for the next version of the GRAPPA PsA treatment recommendations is reviewed.
自成立以来，制定和更新银屑病关节炎（PsA）患者最佳治疗方法的治疗建议一直是银屑病和PsA研究与评估小组（GRAPPA）的一项重要任务。尽管GRAPPA PsA建议的最新版本仅在几年前才完成，但自其发布以来，PsA的治疗方法和治疗手段已经取得了许多重大进展。由于这些进展，再次更新建议的工作已经开始。近年来，制定指南（或治疗建议）的标准方法也有所发展。在此，回顾了GRAPPA PsA治疗建议下一版将采用的方法依据。
